Drug intelligence / Profile preview

GKIND009A

Development stage: Preclinical
Lead developer: China Resources Guokang Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

GKIND009A is a small molecule potassium-competitive acid blocker (P-CAB) being developed by China Resources Guokang Pharmaceutical. It is designed to treat reflux esophagitis by inhibiting the gastric H+/K+-ATPase enzyme (the proton pump). Unlike traditional proton pump inhibitors (PPIs) that require acid activation and bind covalently, P-CABs like GKIND009A competitively inhibit the pump by binding to the potassium-binding site. This mechanism allows for a more rapid onset of action, longer-lasting acid suppression, and better control of nocturnal acid breakthrough. The drug is currently in the IND-enabling (pre-clinical) stage of development.

Other names: GKIND009AGKIND-009AGKIND 009A

Targets

ATP4A (Potassium–transporting ATPase alpha chain 1)

Beyond the preview

Go deeper on GKIND009A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GKIND009A.

Explore the full profile